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An in-vitro study to determine the feasibility of combining Bone Marrow Concentrate with BST-Cargel as a 
treatment for cartilage repair 
 
1.  Introduction 
The microfracture (MF) technique represents a first-line treatment option for small to medium size full-
thickness cartilage defects in the knee, showing a decrease in pain and improved knee function after 1- or 2-
year follow-up
1–3
. In marrow-stimulating procedures, perforations to the subchondral bone allow blood-
marrow and marrow- derived cells to migrate into the holes and defect forming a blood clot. The subsequent 
wound repair cascade comprised of an acute inflammatory response and cell chemotaxis leads to the 
generation of a vascularized granulation tissue, and the potential proliferation of pluripotent mesenchymal 
progenitor cells with a capacity to differentiate into multiple mesenchymal cell types
4
. Bone remodeling can 
proceed along with the induction of chondrogenesis, that resembles endochondral ossification, to form new 
bone in deeper zones and fibrous or fibrocartilaginous tissues in the more superficial chondral region
1,5,6
. 
However, longer term follow-up has demonstrated increasing failure over time with the MF technique
7,8
 
particularly in lesions >4cm
2  9
. As a consequence, clinicians and researchers have tried to improve MF 
results by augmenting the blood clot with various scaffolds, a treatment termed Autologous Matrix Induced 
Chondrogenesis (AMIC). The quality of the data regarding the results for AMIC is currently insufficient to 
recommend one scaffold over another with few prospective studies comparing the results of AMIC to MF or 
Autologous Chondrocyte Implantation
10
. 
BST-CarGel® (Piramal Life SciencesSmith & Nephew, Bio-Orthopaedic DivisionAndover, Massachusetts) 
was developed by Hoemann et al. to stabilize the blood clot in the cartilage lesion following microfracture by 
dispersing a soluble polymer scaffold containing chitosan throughout the blood
11,12
. Chitosan is an abundant 
glucosamine polysaccharide derived from the exoskeleton of crustaceans with low toxicity along with good 
biocompatibility, biodegradability, and tissue adhesive properties
13
. By dissolving chitosan in an aqueous 
glycerophosphate buffer
11
, BST-CarGel® is obtained as a liquid chitosan solution having physiological pH. 
When mixed with fresh, autologous whole blood, BST-CarGel® does not interfere with normal coagulation, 
but reinforces the resulting clot by impeding its retraction
14
. The increased clot adhesivity within the lesion as 
a consequence of chitosan's cationic nature ensures prolonged activation of tissue repair processes by 
maintaining critical blood components above the marrow access holes
12,14,15
. 
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An 80 patient prospective randomised controlled trial of BST-CarGel® versus microfracture for the treatment 
of isolated full-thickness lesions in the knee resulted in more voluminous, higher quality cartilage repair at 1 
year
13
. The benefit was sustained over 5 years, supporting the hypothesis that BST-CarGel® increases the 
consistency of cartilage repair and enhances long-term structural superiority compared with MFX
16
. The 
study was not powered for clinical outcome and no significant difference in clinical scores was seen between 
groups. 
The potential flaw in the AMIC process is the continued need for the microfracture to provide a source of 
pluripotent cells in order to induce repair. The bone changes induced by the microfracture potentially will 
compromise the long-term results. Bone overgrowth following micro fracture has been reported in up to 80% 
of cases
17
, with its presence associated with a ten times increased rate of failure
18
. In an attempt to avoid 
microfracture researchers have explored the potential of using bone marrow concentrate (BMAC) as an 
easily accessible source of pluripotent cells, with promising results reported in the literature
19,20
. There is little 
data within the literature regarding the most effective scaffold/BMAC combination with previous work 
suggesting cell retention as a potential issue with textile-based scaffolds
21
. 
This study aimed to determine whether BST-CarGel® can be mixed with BMAC to create a cell seeded 
implant with comparative properties to standard BST-CarGel® mixed with blood. We also aimed to confirm 
cell retention and viability within the BST-CarGel®/BMAC clots. 
 
2.  Methods 
Ethical approval was obtained to perform the study from the regional ethical committee reference 
12/EE/0136. Twelve patients undergoing cartilage repair surgery using BMAC were consented to take part. 
The in vitro testing model used was a validated model developed by Piraimal and one used to undertake 
quality assurance testing of the chitosan product. Six conditions were tested: 1. BST-CarGel® mixed with 
Whole Blood (CG-WB) 2. BST-CarGel® mixed with Bone Marrow (CH-BM) 3. BST-CarGel® mixed with 
Bone marrow concentrate (CG-BMAC) 4. Whole Blood (WB) 5. Bone marrow (BM) 6. Bone marrow 
concentrate and batroxobin (Plateltex®, Prague, Czech Republic)ibin (BMAC-BTX). Figure 1. 
For each patient 10 mLs of blood was taken at the time of anesthesia induction. Bone marrow collection was 
then undertaken from the anterior iliac crest by the senior author (MS) using a Jamshidi needle pre-rinsed 
with 1:1000 heparin. 60mL of bone marrow was then withdrawn into 6 x 10mL syringes pre-filled with 1 mL of 
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1:1000 heparin solution. Finally, 10 mL of bone marrow was withdrawn into an empty 10 mL syringe. The 
Harvest®, SmartPrep2® system (Smart PRePVR, Harvest Technologies, Plymouth, MA) was used to 
prepare the BMAC as this was found to provide the optimum BM to plasma ratio on preliminary testing. The 
60mL of anti-coagulated bone marrow was first transferred into the MarrowPREP filter bag (to remove bone 
spicules) and then the filtered marrow was transferred into the SmartPrep®2 container, for centrifugation as 
per device instructions. After centrifugation, approximately 6mL of BMAC was obtained on average. BST-
CarGel® reconstituted product was prepared as per the instructions of use prior to mixing with blood, bone 
marrow (BM) and bone marrow concentrate (BMAC). Batroxobin enzyme (BTX, Plateltex®, Prague, Czech 
Republic) was used as external clotting agent to re-activate the BMAC (which contained anti-coagulant) 
specimen. Lyophilized BTX (5 U) was re-suspended with 0.5mL of 10% Calcium Gluconate (CaG). Once 
BST-CarGel® and BMAC was mixed, BTX was added immediately before dispensing these mixtures into 
glass tubes. 
For each of the test conditions, approximately 350μL of mixture was placed in a glass test tube seated in a 
water bath at 37°C for 60 minutes. The time taken for a half sphere clot to form at the base of the test tube 
was recorded. The % clot retraction and macroscopic structure of each generated clot was evaluated at 60 
minutes. Three test tubes were used for each test condition. The BST-CarGel®/specimen clot samples 
should be "clotted" or "clotted on the edges, with a fragile or liquid" centre within 15 min to be considered 
acceptable and comparable to BST-CarGel®/blood clots. 
Percentage of clot retraction was evaluated based on the volume of serum extruded from the clot in the test 
tubes during contraction. After the 60 minute clotting period at 37°C, the glass tubes were removed from the 
water-bath and their weight individually (including the clot and serum) recorded. All liquid (serum or un-
clotted blood) extruded from the clot was carefully removed using a 1mL syringe with an 18G 11⁄2 needle 
without disrupting the clot. The tube with only the clot inside was then weighed. The % of clot retraction was 
calculated as the % ratio of difference in weights between the clot samples with and without serum using the 
following formula (Equation 1): 
 
% 𝑐𝑙𝑜𝑡 𝑟𝑒𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 = 100 − (
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑐𝑙𝑜𝑡 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑠𝑒𝑟𝑢𝑚(𝑔) − 𝑀𝑎𝑠𝑠 𝑜𝑓 𝑒𝑚𝑝𝑡𝑦 𝑡𝑢𝑏𝑒(𝑔)
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑐𝑙𝑜𝑡 𝑤𝑖𝑡ℎ 𝑠𝑒𝑟𝑢𝑚(𝑔) − 𝑀𝑎𝑠𝑠 𝑜𝑓 𝑒𝑚𝑝𝑡𝑦 𝑡𝑢𝑏𝑒(𝑔)
× 100) 
Equation 1 
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The clots without serum from the % clot retraction test were used to assess macroscopic appearance in all 
groups. The clot color, firmness and shape along with the presence of fragmentation were documented. 
 
 
Histological analysis 
Toluidine blue staining method was chosen to evaluate clot homogeneity as it specifically stains each 
component throughout the clot: - Erythrocytes: blue (blue-green); - White blood cells: dark purple; - Chitosan: 
light blue. Briefly, blood clots were fixed in 10% Neutral Buffered Formalin and then cut into 2 halves through 
the middle and the cut face of the clot was placed face down into the embedding block. The paraffin blocks 
were then sectioned into 5μm slices and mounted on glass slides. Two slides were prepared for each 
sample. These slides were then stained following the toluidine blue staining method and digitally scanned 
and viewed at magnifications up to 40X to evaluate the clot mixing homogeneity. The criteria for acceptable 
histology results are defined in table 1. 
 
Cell culture 
Clots were cultured in the glass tubes in 2mL of chondrogenic or non-chondrogenic media which was 
refreshed every 2 days. All clots were stored in a cell culture incubator at 37C and 5% CO2. 
Chondrogenic media: 
DMEM/F-12 (50%/50% vol. mix, Gibco 21331-046, Life Technologies, UK) with 1%vol, ITS-X (Gibco 51500-
056, Life Technologies, UK), 2.4%vol HEPES Buffer (H0887, Sigma-Aldrich, UK), 2.4%vol L-Glutamine 
(G7513, Sigma-Aldrich, UK), 1%vol Penicillin/Streptomycin (P4333-20ML Sigma-Aldrich, UK), 100nM 
Dexamethasone (Sigma-Aldrich, UK) , 27.5ug/mL Ascorbic Acid (2-phospho-L-ascorbic acid (49752-10G, 
Sigma-Aldrich, UK) 1.25ug/mL Bovine Serum Albumin (A8806-1G, Sigma-Aldrich, UK) and 10ng/mL TGF-β1 
(PHG9214, Life Technologies). 
Live-Dead staining 
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Clots were transferred from the glass test tubes to 35mm live cell imaging dishes (CELLview 627860, 
Greiner Bio-One, UK). Calcein AM stock solution of 4μM was prepared in anhydrous DMSO, while a 
propidium Iodide stock solution of 2mM was prepared with a 1:4 v/v mix of DMSO/ultrapure water. A working 
live/dead staining solution was then prepared by adding 0.5μL of stock Calcein AM and 2μL of stock 
propidium to every 1mL DMEM/F-12 culture media (2mL of live/dead working solution is required per clot). 
Samples were stained by adding 2mL of the live/dead working solution to the culture dish containing the clot 
and incubating for 15 minutes in a cell culture incubator at 37C and 5% CO2. 
Confocal fluorescence imaging 
Zeiss LSM 710 confocal fluorescence unit attached to a Zeiss Observer.Z1 microscope with a heated stage 
(Carl Zeiss Ltd., UK). Live and dead dyes were excited and the fluorescence collected independently as 
follows - calcein AM: excited with 488nm laser, ~3% transmission, spectral detection range: 500nm-592nm. 
Propidium iodide: excited with 543nm laser, ~7% transmission, spectral detection range: 595nm-704nm. 
Four frames were collected per channel and averaged to form a final image slice for each channel. Images 
were acquired at 1024x1024 pixels and 16-bit colour depth. 
A global view of the clot was obtained by acquiring a 2D single image slice with 12μm slice thickness using a 
x10 (EC Plan-Neofluar 10x/0.30 M27) objective lens. Higher magnification 3D z-stacks were acquired using 
a x20 (EC PlanN NA=0.5 DIC) objective lens. 
 
3.  Results 
The results of the blood, bone marrow and BMAC analysis pre and post centrifugation is shown in table 2. 
The white cell concentration on average increased by a factor of 6.9 following centrifugation of the bone 
marrow. 
The macroscopic appearance of the BST-Cargel clots were all very similar. The clots in all BST-CG groups 
were classified as a pass at the 15 minute observation time point (or less). However, 2 out of 12 bone 
marrow specimens were not fully clotted within 15 minutes. This may be attributable to the fact that these 
particular samples might have been contaminated with whole blood, which would have increased the 
coagulation time by dilution. Indeed, it is usual to observe that the whole blood condition is not entirely 
clotted after 15 minutes. On the other hand, the use of batroxobin accelerated the clotting of CG/BMAC 
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samples and reduced the clotting time to approximately 5 minutes on average. The CG-BMAC clots were 
softer on manipulation and handling compared to the CG-WB and CG-BM groups. 
The clot retraction for all test conditions are shown in Table 3. The CGWB samples demonstrated 2.6% 
retraction, which is standard retraction for the BST-CG product. CG-BM demonstrated very similar 
contraction however the CG-BMAC samples had a mean contraction of 10.3%. 
A summary of the data on clot morphology and composition for a single patient is shown in Figure 2. CG-WB 
clots exhibited the typical uniform distribution of chitosan without any chitosan aggregates. Most Red blood 
cells had the typical biconcave morphology with small areas of agglutination. The CG-BM clots showed 
similar appearances with all clots classified as a pass. 
The CG-BMAC clots demonstrated mostly homogenous distribution of chitosan throughout the clot and the 
RBCs were biconcave in shape with small areas of agglutination. However, there was variation observed in 
this group. 8/24 clots examined demonstrated roundish/swollen RBCs without the typical biconcave 
morphology. The space around the RBC’s was filled up with a light blue "film" of uncertain origin. A high 
number of other cell types were visible as well as adipocytes. Figure 3. 
Cell viability 
The clots started to fragment in culture between day 3-5, leading to loss of mostly live cells adhered to the 
gel material during media changes. As can be seen over the image timepoints in Figure 4 c-e, the cell 
density decreased across the clot fragments, which reduced the total cell count and increased the range in 
estimated cell viability over time. The average viability dropped to 70-73% at day 3-7 due to the loss of cells 
attached to broken clot fragments, but homogenization of the remaining clot and clot fragments to recover 
the entire cell population showed that the overall viability was still >86%. 
 
 
4.  Discussion 
The main findings of this study were that BM and BMAC (processed using the Harvest system and 
reactivated with batroxoibin)) when combined with BST cargel produced a product that had similar clot 
retraction, macroscopic properties and histological appearance to standard BST-CarGel® mixed with blood. 
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Mononucleated cells from the BMAC were retained within the scaffold and remained viable until clot 
dissolution in vitro. 
Microfracture results in bone overgrowth which reduces the volume of the cartilage regenerate
18
. The 
subchondral bone is also postulated to become stiffer which results in increased stress on the fibrocartilage 
regenerate. These are thought to be some of the reasons in association with poor clot stability
14
 why 
microfracture results appear to be less durable than those for ACI - a technique which does not disrupt the 
subchondral bone. The application of BMAC to chondral defects has shown promising results in both animal 
models
22
 and in humans
20,23,24
. The aim is to provide a source of mono-nucleated cells which could augment 
and drive host repair and consequently this would negate the need to penetrate the subchondral bone. 
However, there is very little literature to guide the decision as to which is the ideal scaffold to deliver and 
retain the cells within a chondral defect. 
Bone marrow from the iliac crest has been shown by De Girolamo et al. to contain more cells with an MSC 
phenotype (CD34−/CD45low/ CD271high) (0.04%) compared to the subchondral location of the defect
25
 
(0.02%) and so potentially its application in a chondral defect would result in increased MSC concentration 
compared to that provided by microfracture. By centrifuging the BM to create BMAC the mononucleated cell 
concentration can be increased further by a factor of 6. However, the process of centrifugation requires 
anticoagulation which affects the normal clotting process that BST-cargel requires to gelate. Batroxabin is a 
thrombin-like enzyme of Bothrops atrox moojeni venom, it specifically cleaves fibrinogen alpha chain, 
resulting in the formation of non-crosslinked fibrin clots. In preliminary testing this enzyme was found to be 
the most effective method of reactivating the BMAC without causing excessive contraction. This is believed 
to be due to its mechanism of coagulation via fibrin and not platelet activation
26,27
. Batroxobin has been used 
in clinical trials aiming to reduce perioperative blood loss in spinal surgery
28
 and to prevent 
restenosis/reocclusion following angioplasty
29
.  
The main aim of the study was to replicate the macroscopic and histological appearance of the standard 
BST Cargel using BMAC instead of whole blood, given the scaffolds proven effectiveness to improve the 
quality of the cartilage regenerate in both an animal model and in humans. Hoemann et al. (Hoemann et al. 
2005b) demonstrated in a sheep model that the application of a chitosan-glycerol phosphate/blood clot to 
condylar defects resulted in a net increase in fill (52%), a modest but significant increase in hyaline character 
(86%) with more columnar organization and a complete restoration of normal glycosaminoglycan levels 
compared to microfracture alone
14
. Stanish et al retrieved 38 repair tissue biopsies at 1 year post-treatment 
 8 
as part of a RCT of BST-CarGel® versus microfracture alone in humans
13
.  They found significantly better 
zonal organization and collagen characteristics for the BST- CarGel® biopsies over the MFX biopsies.  
Whilst there was no clinical difference detected between the two groups at 12 months, it is recognised that 
improved collagen content and zonal organization are necessary components for long-term durability of 
repair cartilage given collagen breakdown is considered to be a critical step in the progression of 
osteoarthritis. 
The aim of BST-cargel is to stabilise the clot produced by microfracture and prevent clot contraction within 
the defect. Bone marrow contains less platelets (as platelets are only released into the circulation through 
the cytoplasmic fragmentation of megakaryocytes cells) and less fibrinogen (as this protein is secreted by 
hepatocyte cells into the circulation) than blood. However, the percentage clot retraction of BST-CarGel®/BM 
in this study was within the normal range of percentage clot retraction observed for BST- CarGel®/blood 
clots. These results are likely attributable to the fact that during aspiration of BM, venous blood was also 
aspirated. Therefore, BM is never 100% composed of bone marrow elements, but is also "contaminated" 
with venous blood. In this experiment, bone marrow elements were observed on histology (i.e. adipocytes 
cells and precursor's cells surrounded with collagen structures) and therefore the BM specimen collected 
was effectively composed of bone marrow and not only of blood. CG/BMAC demonstrated contraction on 
average of 10% which we feel is within an acceptable clinical range. This increased contraction is likely due 
to the increased platelet activation and augmented clotting process. This would be in agreement with the 
reduced clotting time of less than 5 minutes in this group compared to the 15minutes in whole blood control. 
Macroscopically, the CG-BMAC clots were softer compared to the CG clots generated using blood and bone 
marrow which is likely due to the increased cellularity of the clots. The structural properties of the cargel clots 
were not objectively compared by undertaking mechanical testing and therefore were not objectively 
quantified during this study . The senior author (MS) has implanted CG/BMAC in vivo and the physical 
properties were comparable to CG-WB and appear to be sufficient to allow stable implantation. 
The histology of the BST-cargel/BMAC clots were all satisfactory and on the whole showed similar structure 
to the BST/WB clots. There was even distribution of chitosan with biconcave structure of the rbc's in the 
majority of clots. There was variation in the CG-BMAC clots, with 36% of clots demonstrating a number of 
blue patches. We believe these represent de-granulated platelet aggregates, fibrin, and chitosan with no red 
blood cells. This was likely secondary to the heparinized blood, as calcium is not chelated, it permits platelet 
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aggregation and partial platelet activation following the addition of batroxabin. Whether the presence of this 
variation would affect the scaffold performance and the clinical outcome is unknown. 
The viability data demonstrated that the cells remained viable until clot disruption.  The poly-cationic nature 
of chitosan facilitates adhesion to negatively charged surfaces of tissues and cells
15
, including cartilage. This 
results in increased clot adhesivity within the lesion and contributes to cell retention. This will potentially 
result in prolonged activation of the tissue repair processes by maintaining greater numbers of 
mononucleated cells within the lesion. The importance of cell retention at the defect site has been 
demonstrated by Kim et al., who demonstrated that implantation of MSC's in a chondral defect was superior 
compared to injection, probably secondary to more effective delivery of paracrine factors and less cell 
death
30
. 
Whilst a number of investigators have assessed the growth and chondrogenic potential of bone marrow 
derived mesenchymal stem cells on different scaffolds
31–35
 there are very few studies which have undertaken 
the same using BMAC. Grigolo et al. seeded BMAC on a nano-structured bio-mimetic three-layer gradient 
scaffold composed of type I collagen and magnesium enriched hydroxyapatite
36
. They were able to 
demonstrate that BMAC could differentiate along chondrogenic and osteogenic pathways as evaluated by 
the expression and production of specific matrix molecules. Cavallo et al. seeded 0.1ml of BMAC on a 0.5cm 
x 0.5cm pieces of hyaluronic scaffold (Hyaff 11) and cultured them for 52 days
37
. They demonstrated that 
cells within BMAC seeded onto the Hyaff-11 scaffold and were able to differentiate down a chondrogenic 
pathway, expressing and producing sulfated glycosaminoglycans, SOX-9, aggrecan, and collagen type II. 
However, this is in contradiction to the findings of Kohli et al. who seeded 30μL of BMAC on Chondro-Gide®, 
Alpha Chondro Shield® and Hyalofast®
21
. All cell-seeded scaffolds were fed with standard culture media, 
three times a week for a period of four weeks. Alpha Chondro Shield and Hyalofast demonstrated the best 
initial cell seeding with BMAC on all three scaffolds remaining viable after 1 day and 1 week. Very few viable 
cells were visualised after 7 days and no cells were seen to be incorporated in either of the three scaffolds 
after 4 weeks in culture with cell retention postulated as the main cause.   
The viability tests in this study were only carried out to 7 days. This was secondary to technical difficulties 
due to rapid clot degradation in vitro. BST-CarGel® degrades in vivo over a period of 5 weeks, however the 
clots in all test groups began to lose structural integrity after 7-10 days in media. We hypothesised the 
fragmentation occurred due to a combination regular media replacement gradually breaking its adherence to 
culture surfaces (despite best efforts to be careful) and loss of 3D structural support when the clots had to be 
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transferred to imaging dishes to be examined. Culturing the clots in imaging dishes reduced the impact of 
damage from moving the clots but came at the expense of structural support compared to the test tube. We 
also believe that the decreased viscosity of the media compared to synovial fluid penetrated the clots to a 
greater extent resulting in their early disruption. The increased fragility over time meant it became technically 
difficult to avoid scaffold and cell loss and consequently a decision was made not to image beyond the 7-day 
period. 
The results of this study confirm that BMAC can be combined with BST cargel when prepared in a specific 
manner to produce a scaffold which has similar properties to standard BST cargel mixed with blood. BST-
cargel has previously been shown to be a biologically active scaffold, improving histological repair following 
microfracture. By combining BST-CarGel® with BMAC in the manner described, bone marrow derived 
mononucleated cells can be retained within the chondral defect potentially negating the need for 
microfracture. Further in vivo work is required to confirm these potential benefits and determine if this 
combination will result in more durable cartilage repair and improved clinical outcomes. 
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Figure legends 
 
Figure 1. Schematic presentation of the clot variants studied. BMAC: Bone Marrow Aspirate 
Concentrate, a activated using Batroxobin. 
 
Figure 2. 
Example of contraction data, macroscopic appearance and histology for all test conditions. - 
Erythrocytes: blue (blue-green); - White blood cells: dark purple; - Chitosan: light blue. 
 
Figure 3. x40 magnification Toludone blue stain of all studied clot variants. WB: Whole Blood, BM: 
Bone Marrow, BMAC: Bone Marrow Aspirate Concentrate, a activated using Batroxobin. - 
Erythrocytes: blue (blue-green); - White blood cells: dark purple; - Chitosan: light blue. 
 
Figure 4. 
Live cell confocal fluorescence images (a-e) (z-projections) showing the live (green) and dead (red) 
cell populations within a single clot from the study. Images a and b were captured at day 1 in two 
locations in the clot and demonstrate the large number of viable cells spread through lateral cross-
section of a clot. Images c, d and e represent clots at day 3, 7 and 10, respectively where good cell 
viability was maintained. Cell density appears to decrease gradually as the clots gradually break up 
in culture.  The viability plot (f) presents the average cell viability across all samples grouped by 
timepoint with error bars representing range of viability values.  
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